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Abstract
Background: In cholinergic neurons, the hydrolysis of phosphatidylcholine (PC) by a
phospholipase D (PLD)-type enzyme generates some of the precursor choline used for the
synthesis of the neurotransmitter acetylcholine (ACh). We sought to determine the molecular
identity of the relevant PLD using murine basal forebrain cholinergic SN56 cells in which the
expression and activity of the two PLD isoforms, PLD1 and PLD2, were experimentally modified.
ACh levels were examined in cells incubated in a choline-free medium, to ensure that their ACh
was synthesized entirely from intracellular choline.
Results: PLD2, but not PLD1, mRNA and protein were detected in these cells and endogenous
PLD activity and ACh synthesis were stimulated by phorbol 12-myristate 13-acetate (PMA).
Introduction of a PLD2 antisense oligonucleotide into the cells reduced PLD2 mRNA and protein
expression by approximately 30%. The PLD2 antisense oligomer similarly reduced basal- and PMA-
stimulated PLD activity and ACh levels. Overexpression of mouse PLD2 by transient transfection
increased basal- (by 74%) and PMA-stimulated (by 3.2-fold) PLD activity. Moreover, PLD2
transfection increased ACh levels by 26% in the absence of PMA and by 2.1-fold in the presence of
PMA. Overexpression of human PLD1 by transient transfection increased PLD activity by 4.6-fold
and ACh synthesis by 2.3-fold in the presence of PMA as compared to controls.
Conclusions: These data identify PLD2 as the endogenous enzyme that hydrolyzes PC to generate
choline for ACh synthesis in cholinergic cells, and indicate that in a model system choline generated
by PLD1 may also be used for this purpose.
Background 
The synthesis of the neurotransmitter acetylcholine
(ACh)1 in cholinergic neurons is dependent on the avail-
ability of its precursor, choline, most of which is derived
from the circulation (reviewed in [1]) and enters cholin-
ergic neurons via a process catalyzed by a specific trans-
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is stored in membrane phosphatidylcholine (PC). Previ-
ous studies have shown that this choline is liberated from
PC in a one-step reaction, thus indicating that it is pro-
duced by a phospholipase D (PLD, EC 3.1.4.4) -an en-
zyme that hydrolyzes the phospholipid into choline and
phosphatidic acid (PA) [4]. However, the molecular
identity of this PLD remains to be determined.
There are two distinct PC-specific mammalian PLDs,
designated as PLD1 and PLD2 and encoded by separate
genes [5,6]. The two enzymes share 50% amino-acid
identity, however, regulation of their activity and cellular
localization are different. PLD1 is an extracellular signal-
activated phospholipase; its activity rises when receptors
for certain hormones, growth factors, neurotransmitters,
cytokines, and other mediators are activated, and upon
treatment of cells with phorbol esters (reviewed in [7,8]).
Studies using recombinant PLD1 tagged with green fluo-
rescent protein or Flu-epitopes indicate that it is local-
ized in the endoplasmic reticulum, Golgi apparatus, late
endosomes, and plasma membrane ([6], reviewed in
[7]). In vitro, basal PLD1 activity is usually low and can
be stimulated by a variety of factors, including phos-
phatidylinositol 4, 5-bisphosphate (PIP2), protein kinase
C (PKC), and several small GTPases, e.g. ADP ribosyla-
tion factors (ARF) and Rho (reviewed in [7,8]). Regula-
tion of PLD2 is less well understood. The enzyme
exhibits a high constitutive activity in vitro, but it too can
be activated by ARF (reviewed in [7]), and by phorbol es-
ters, in intact cells [6,9]. Several reports have suggested
that PLD2 is mainly localized to the plasma membrane
[6,10], possibly in lipid rafts and caveolar membrane
microdomains [11,12]. Most studies on the physiological
functions of PLDs have focused on the product PA, a sec-
ond messenger involved in mitosis, cellular morphologi-
cal changes and vesicular trafficking (reviewed in [7,13]).
However, the downstream events that occur as a conse-
quence of PLD-generated PA production, and the identi-
ty of target proteins that are directly regulated by PA
remains to be determined. PA can be further metabolized
to diacylglycerol (DAG) and lysophosphatidic acid by PA
phosphohydrolase and phospholipase A2, respectively.
DAG is an activator of certain isozymes of PKC and lyso-
phosphatidic acid acts as an intercellular messenger for
many cell types.
The second product of PLD-catalyzed PC hydrolysis,
choline, is used by all cells as a precursor of PC, and
uniquely by cholinergic neurons as precursor of ACh.
Previous studies have shown that choline derived from
PC is indeed used for ACh synthesis [4,14–16] and that
this choline is generated by a PLD [4,14]. This pathway
may become particularly important when extracellular
circulating choline concentrations are low (e.g. during
dietary choline deficiency) or when ACh synthesis and
release are accelerated by high neuronal activity, thus
generating a high demand for choline [16].
In the present study, we used a cholinergic cell line, SN56
[17], which is derived from the fusion of septal neurons
of postnatal day 21 mice with N18TG2 murine neuroblas-
toma cells, as a model for cholinergic neurons, in order
to determine the possible role of PLD 1 and PLD2 in gen-
erating choline for ACh synthesis. We found that the cells
express exclusively PLD2 and that downregulating PLD2
expression reduces ACh synthesis, while overexpressing
and/or stimulating PLD2 activity increases the synthesis
of the neurotransmitter, indicating that PLD2-catalyzed
hydrolysis of PC generates choline for ACh synthesis in
cholinergic cells.
Results 
PLD2 mRNA was present in SN56 cells (Fig. 1A) while
PLD1 message was undetectable either by Northern blot
(Fig. 1A) or RT-PCR (data not shown). Consistent with
these results an approximately 90 kDa PLD2 protein was
found in SN56 cells by Western blot; however, no PLD1
protein could be detected (Fig. 1B). Positive controls for
these studies showed that our PLD1 probe and antibody
were robust in detecting this PLD isoform in rat brain
(Fig. 1). These data show that SN56 cells express exclu-
sively PLD2 and thus experimental manipulations of the
activity of this PLD isoform were subsequently employed
to determine if this enzyme is capable of producing
choline for ACh synthesis in cholinergic cells. In order to
reduce PLD2 activity in SN56 cells, we sought to inhibit
its expression. The cells were treated with a 25-mer anti-
sense oligonucleotide at different concentrations and
PLD2 mRNA levels were measured. Northern blot
showed that PLD2 mRNA expression was reduced by the
antisense oligonucleotide in a concentration-dependent
manner (Fig. 2A), and that, at the maximally-effective
concentration of the oligo (200 nM), this inhibition
reached 34% (Fig. 2B,C). In contrast, the control oli-
gomer was inactive (Fig. 2B,C). Consistent with these
findings. Western blot showed that the antisense oli-
gomer decreased the PLD2 protein level by about 28%,
whereas the control oligomer had no significant effect on
PLD2 protein expression (Fig. 2D,E). Given the fact that
the transfection efficiency obtained in these experiments
was approximately 30% (as determined with fluorescent
dye-labeled oligonucleotides; data not shown), the re-
sults indicate that, in cells that had taken up the anti-
sense oligomer, the inhibition of PLD2 expression was
complete.
Treatment of a variety of cell types with phorbol esters
activates PLD2 [6,12,18,19]. Thus we hypothesized that
activation of PLD with PMA in SN56 cells would elevate
BMC Neuroscience 2001, 2:16 http://www.biomedcentral.com/1471-2202/2/16intracellular concentrations of its product, choline, and
result in increased ACh production. We tested the effects
of PMA on PLD activity and ACh content in SN56 cells
incubated in a choline-free medium. Under these condi-
tions the choline precursor used for the synthesis of ACh
is derived entirely from the intracellular pool, which in-
cludes the choline in PC [4,15]. Consistent with previous
studies, treatment of the cells with PMA activated PLD
(Fig. 3A). The maximal effects of PMA (3.3 fold increase
in the amount of its product [3H]phosphatidylpropanol
relative to controls) was observed after 45 minutes (data
not shown), a time period employed in subsequent stud-
ies. Free choline accumulation was also significantly in-
creased by PMA. The magnitude of this effect tended to
be small (approximately 15%), presumably because free
choline is a rapidly turning over metabolic intermediate
that does not accumulate in cells (Fig. 3B). Moreover,
PMA stimulated ACh accumulation by 26% (Fig. 3C), in
the cells. The fact that PMA increased both PLD activity
and ACh content provided the initial evidence for a rela-
tionship between the endogenous PLD activity (i.e.
PLD2) and ACh production. In control studies per-
formed in the presence of choline (15 µM) in the medium
PMA had no effect on ACh levels (data not shown), indi-
cating that it did not stimulate the process of ACh syn-
thesis but only the supply of choline.
Next the effect of downregulation of PLD2 activity on
ACh levels was studied in cells transfected with either
control or antisense oligomer and treated with PMA. In
the absence of PMA, the antisense oligomer decreased
PLD2 activity by 19%. Although small, this change was
statistically significant (p < 0.05). In the presence of
PMA, antisense oligomer decreased PLD2 activity by
27% (Fig. 3A). Concomitantly the cellular choline con-
tent was decreased by 30% both in the presence and ab-
sence of PMA by the antisense oligomer (Fig. 3B).
Moreover, the antisense oligomer decreased the cellular
ACh content by approximately 30% compared to control
oligomer treated cells both in the presence and absence
of PMA (Fig. 3C). These results indicate that downregu-
lation of PLD2 activity by antisense oligomers in SN56
cells decreases not only the endogenous PLD2 activity
but also the intracellular choline and ACh content. These
Figure 1
SN56 cells express PLD2 but not PLD1 mRNA and protein. Total RNA or protein lysates were prepared and sub-
jected to Northern or Western blot analyses as described in the Experimental Procedures. A. Northern blot. Twenty µg of
total RNA was subjected to electrophoresis on a 1.0% agarose gel and hybridized respectively with a mouse PLD2 probe, a
human PLD1 probe and a mouse G3PDH probe. B. Western blot. A polyclonal anti-mouse PLD1 antibody and a polyclonal
anti-human PLD2 antibody were used as primary antibodies. Rat brain total RNA (A) and protein lysates (B) were used as pos-
itive controls.
BMC Neuroscience 2001, 2:16 http://www.biomedcentral.com/1471-2202/2/16results are consistent with the hypothesis that PLD2 can
generate choline for ACh synthesis in SN56 cells.
To further confirm this hypothesis, we transiently trans-
fected the cells with a mouse PLD2 expression plasmid.
Overexpression of PLD2 for 48 hours in the cells caused
a 74% increase of basal PLD2 activity and this activity
was further increased by PMA by 3.2-fold (Fig. 4A). To
examine the ACh synthesis and choline turnover in these
PLD2 transfectants, the cells and the media were collect-
ed and ACh and choline content were measured. In the
absence of PMA, overexpression of PLD2 alone in-
creased intracellular ACh levels by 26% and choline con-
centrations in the medium by 57%. In the presence of
PMA, intracellular ACh levels and choline concentration
in the medium rose further in the PLD2 transfectants
Figure 2
PLD2 antisense oligonucleotides reduce endogenous PLD2 mRNA expression and protein levels in SN56 cells.
SN56 cells were transfected with either control or antisense oligonucleotides as described in the Experimental Procedures.
Two days later PLD2 gene expression was assessed by Northern blot analysis (A-C) as described in Fig. 1. G3PDH was used
for normalization (A-C). For Western blots 40 µg of lysate protein was subjected to SDS-PAGE. A polyclonal anti-human PLD2
antibody was used first to detect PLD2, the blot was stripped and rehybridized with a monoclonal anti-mouse actin antibody
for normalization (D,E). A. Concentration-response curve to the antisense oligonucleotide. B. Comparison of the effects of the
antisense and control oligonucleotides on PLD2 expression. The cells were transfected with 200 nM of either control or anti-
sense oligomer as indicated. C. Quantification of results presented in B. Intensity of the hybridization bands was normalized to
that of G3PDH. The antisense oligomer reduced PLD2 expression by 34%, *p < 0.05. Data shown are from 3–6 experiments
and expressed as average ± SEM. D. The antisense oligomer reduced PLD2 protein expression as compared to mock-treated
and control oligomer-transfected cells. E. The intensity of the PLD2 bands was quantified using NIH Image 1.62 and normalized
to that of actin. The antisense oligomer reduced the PLD2 protein level by 28% compared to controls, *p < 0.05. The results
are from 3 experiments and expressed as average ± SEM.
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the control cells (Fig. 4B,C). Together with the data pre-
sented above, these results show that up-regulation of
PLD2 activity by overexpression and/or stimulation with
PMA increases intracellular ACh levels.
A recent immunohistochemical study of PLD1 expres-
sion in rat brain showed that this PLD isoform was ex-
pressed in neurons in medial septum, cranial motor
nuclei and ventral spinal cord [20], all areas of the cen-
tral nervous system enriched with cholinergic neurons.
These data raised the possibility that certain populations
of cholinergic neurons may express PLD1 in addition to,
or instead of, PLD2. Therefore we transfected SN56 cells
with PLD1 expression construct, in order to determine if
choline generated by this enzyme could be used as ACh
precursor. Transfection of PLD1 into SN56 cells resulted
in increased PLD activity and ACh synthesis in a fashion
similar to that observed in PLD2 transfectants (Fig. 5) in-
dicating that choline generated by PLD1 was converted
to ACh.
Discussion 
In the present study, we sought to establish which PLD
isoform is the endogenous enzyme that generates the
choline precursor for ACh synthesis in cholinergic neu-
rons using, as a model, the SN56 basal forebrain cell line.
We found that these cells expressed exclusively PLD2, a
property that facilitated subsequent experiments. First,
antisense oligonucleotides were used to down-regulate
endogenous PLD2 activity. Although only 30% of the
cells took up the oligonucleotides, PLD2 mRNA, protein
expression, and activity were reduced proportionally to
the transfection efficiency of the antisense oligomer,
demonstrating high efficacy of this technique in the
transfected cells. Significantly, intracellular choline and
ACh content were similarly decreased by the antisense
oligonucleotides, indicating that PLD2-catalyzed hydrol-
ysis of PC provides choline for ACh synthesis. Next,
PLD2 activity was up-regulated by either overexpressing
a mouse PLD2 protein and/or by stimulation with PMA.
Both PLD2 overexpression and stimulation with PMA
increased PLD activity, choline production, and ACh ac-
cumulation. Moreover, PLD2 transfection and PMA
treatment had a synergistic effect on PLD activity and
ACh levels.
Our observation that PLD2 but not PLD1 was present in
SN56 cells raised the possibility that the former might be
preferentially expressed in cholinergic neurons. The data
are consistent with the report that a variant of PC12 cells
also express exclusively PLD2 [18] and this expression is
stimulated by nerve growth factor [18], a treatment
known to upregulate the cholinergic phenotype of PC12
cells [21,22]. PLD2 mRNA is abundant in many regions
of the adult rodent central nervous system [6,23], includ-
ing cerebellum, frontal cortex, hippocampus, hypothala-
mus, midbrain, brainstem, striatum, and spinal cord
[24]. The latter three regions are enriched with cell bod-
ies of cholinergic neurons. PLD1 is also highly expressed
Figure 3
PLD2 antisense oligonucleotides down-regulate PLD2 activity, and acetylcholine and choline levels in SN56
cells. SN56 cells were transfected with either control or antisense oligonucleotides as described in the Experimental Proce-
dures. After 48 hours the cells were preincubated for 20 minutes in choline-free medium and then incubated in fresh choline-
free medium containing 50 µM neostigmine with or without 100 nM PMA for 45 minutes. PLD activity in the intact cells (A)
and the intracellular choline (B) and acetylcholine (C) content were measured. The data were analyzed by two-way ANOVA
and Fisher's post hoc test and are expressed as average ± SEM. The asterisks indicate a significant difference between the anti-
sense and control transfectants (A-C). A. Effect of antisense oligonucleotides on PLD activity. The effect of PMA treatment is
statistically significant in all groups. B. Effect of antisense oligonucleotides on intracellular choline level. C. Effect of antisense
oligonucleotides on intracellular ACh level. The effect of PMA treatment is statistically significant in all groups.
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septum, cranial motor nuclei and ventral spinal cord
[20], all of which are likely cholinergic. However, no data
are currently available on the possible coexpression of
PLD1 and/or PLD2 and cholinergic markers (e.g. choline
acetyltransferase) in vivo. Transfection of PLD1 into
SN56 cells resulted in increased PLD activity and ACh
production suggesting that PLD1, like PLD2, could po-
tentially be used to supply choline for ACh synthesis.
Thus, while the catalytic activities of both PLD1 and
PLD2 appear to be equivalent in generating choline for
ACh synthesis in transfected cells, it is possible that the
modes of regulation of their activity might specify which
one is expressed in a particular population of cholinergic
neurons in vivo. It will be important to determine the
mechanisms that control the expression of the two PLD
isoforms and their possible relationships with the mech-
anisms that regulate the cholinergic phenotype.
Stimulation of PLD activity by PMA and the resulting in-
crease of ACh synthesis from PLD-generated choline in-
dicates that this pathway is regulated by PMA-
responsive PKC isozymes. In vivo, this form of regulation
of ACh synthesis would be controlled by neurotransmit-
ters released by neurons that innervate particular cholin-
ergic cells. There are multiple neurotransmitters whose
receptors are coupled to PKC-dependent activation of
PLD [7], and thus this mode of regulating the availability
of choline for ACh synthesis is likely to be widespread.
Significantly, among the five subtypes of muscarinic ACh
receptors (MAChRs), Ml and M3 receptors have been
shown to efficiently activate PLD (and PKC) in various
cell types [26–30], whereas activation of PLD by M2 and
M4 receptors is less robust [26]. These observations sug-
gest that in a cholinergic synapse, ACh released into the
synaptic cleft might stimulate PLD activity leading to a
release of choline that could be used for ACh synthesis.
Since these MAChRs may be present on the pre- and
postsynaptic neurons [31], this choline may be derived
from PC residing in the membranes of either. However,
while the presynaptically-derived choline released into
the cytoplasm can be converted directly to ACh, the
choline released by the postsynaptic cell must be initially
taken up by the cholinergic nerve terminals. Our previ-
ous results in cholinergic human neuroblastoma LA-N-2
cells indicated that the choline moiety from PC break-
down was released directly into the cytoplasm [4] and a
kinetic study using [3H]choline in BHK cells also showed
that choline was initially released inside the cells by
PMA-activated PLD and then rapidly appeared in the
medium [32]. Consistent with the latter study, we also
observed a rise in the medium choline levels in SN56
cells transfected with either PLD1 or PLD2 and treated
with PMA.
Although it is clear that the PLD-generated choline is ef-
ficiently utilized by cholinergic cells (LA-N-2 and SN56)
as a precursor of ACh, the quantitative significance of
this pathway and mechanisms that regulate it remain to
be fully determined. Studies on a variety of preparations
Figure 4
Overexpression of PLD2 in SN56 cells increases enzyme activity, acetylcholine synthesis and choline content
in the medium. The cells were transfected with the expression plasmid as described in the Experimental Procedures. After
48 hours the cells were treated as described in Fig. 3 and PLD activity in intact cells (A), choline content of the medium (B), and
intracellular ACh content (C), were measured. The data were analyzed by two-way ANOVA and Fisher's post hoc test and are
expressed as average ± SEM. The asterisks indicate a significant difference between the PLD2 and mock transfectants (A-C). A.
Effect of PLD2 overexpression on PLD activity. The effect of PMA treatment is statistically significant in all groups. B. Effect of
PLD2 overexpression on media choline level. The effect of PMA treatment is statistically significant in PLD2 transfectants. C.
Effect of PLD2 overexpression on intracellular ACh level. The effect of PMA treatment is statistically significant in PLD2 trans-
fectants.
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BMC Neuroscience 2001, 2:16 http://www.biomedcentral.com/1471-2202/2/16indicate that most of the choline used for ACh synthesis
is derived from the extracellular space (reviewed in [1])
and therefore the PLD pathway has to be considered as
an accessory process. Interestingly, PLD activity is up-
regulated in the hippocampus of rats whose mothers
consumed a choline-supplemented diet during pregnan-
cy [33]. Given that prenatal choline supplementation im-
proves memory and attention [34], two cognitive
functions that require the hippocampal cholinergic sys-
tem, it is possible that the upregulated PLD pathway un-
derlies, at least in part, the cognitive enhancement
observed in the prenatally choline-supplemented ani-
mals.
Abnormalities in the PLD-mediated release of choline
would be expected to result in an impairment of cholin-
ergic neurotransmission and/or in a generalized mal-
function of cholinergic cells. Alzheimer's disease (AD) is
characterized by such a malfunction together with de-
generation of basal forebrain cholinergic neurons, and it
is thought that memory loss in this disease is partly
caused by this cholinergic lesion [35]. In vitro studies
point to two novel mechanisms that might cause dysreg-
ulation of PLD2 activity in AD. The first is based on ob-
servations that PLD2 is inhibited by α-synuclein [36], a
protein of unknown function that accumulates in the
amyloid deposits in AD brain. Normally α-synuclein is
present in the synaptic nerve terminals (including those
of cholinergic neurons [37,38]) but in AD its processing
is altered, causing it to be abnormally deposited in
plaques composed primarily of aggregates of β-amyloid
peptide [39]. However, how this abnormal turnover of α-
synuclein contributes to the pathophysiology of AD re-
mains to be determined. Recent in vitro observations
that α-synuclein is phosphorylated by G protein-coupled
receptor kinases, and that this phosphorylation relieves
its inhibitory action on PLD2 [40], suggest a novel mech-
anism by which neurotransmitter receptors (including
muscarinic receptors) might modulate PLD2 activity.
Since multiple receptor classes are affected by the patho-
physiological processes of AD [41], abnormal phosphor-
ylation of α-synuclein may contribute to both altered α-
synuclein turnover and abnormal regulation of PLD2 ac-
tivity. The second set of observations indicate that reac-
tive oxygen species (ROS) activate PLD2 in a PKC-
dependent manner [9]. There is much evidence that ROS
generation is upregulated in AD brain [42]. Thus, it is
possible that PLD2 may be activated in this disease re-
sulting, perhaps, in dysregulation of PC metabolism. In-
deed evidence of an accelerated PC turnover has been
repeatedly observed in post-mortem samples of AD
brain [43–47] as well as in an in vitro model of this dis-
ease characterized by the generation of ROS [48].
Conclusions 
Most of the previous studies on the physiological func-
tions PLDs have concentrated on the role of its product,
PA [7]. Our data show that PLD has a dual function in
cholinergic cells, as the second product of its activity,
choline, is used as a metabolic precursor of ACh, and
Figure 5
Overexpression of PLD1 in SN56 cells increases enzyme activity, acetylcholine synthesis and choline content
in the medium. The cells were transfected with the hPLD1 expression plasmid as described in the Experimental Procedures.
After 48 hours the cells were treated as described in Fig. 3 and PLD activity in intact cells (A), choline content of the medium
(B), and intracellular ACh content (C), were measured. The data were analyzed by two-way ANOVA and Fisher's post hoc test
and are expressed as average ± SEM. The asterisks indicate a significant difference between the PLD1 and mock transfectants
(A-C). A. Effect of PLD 1 overexpression on PLD activity. The effect of PMA treatment is statistically significant in all groups. B.
Effect of PLD1 overexpression on media choline level. The effect of PMA treatment is statistically significant in PLD1 transfect-
ants. C. Effect of PLD1 overexpression on intracellular ACh level. The effect of PMA treatment is statistically significant in
PLD1 transfectants.
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BMC Neuroscience 2001, 2:16 http://www.biomedcentral.com/1471-2202/2/16suggest that this pathway may be regulated by the type of
PLD isoform expressed in a particular class of choliner-
gic neurons. In our basal forebrain-derived SN56 cells,
this isoform is PLD2. However, our observations that
PLD1 overexpression increases ACh production form en-
dogenous sources suggest that PLD1 may serve the same
function as PLD2 in other cholinergic cells. Moreover,
the data showing that this pathway is stimulated by
PMA, suggest that it is subject to regulation by PKC-acti-
vating neurotransmitters. The physiological, and possi-
ble pathophysiological significance in neurological
diseases, of this pathway remains to be determined. It
will also be important to determine how cholinergic cells
regulate the metabolism of PA – a compound with mul-
tiple signaling and structural functions – when the PLD
pathway is stimulated to meet the demand for choline.
Materials and Methods 
Materials 
Dulbecco's modified Eagle's medium (DMEM), fetal bo-
vine serum (FBS) and Lipofectamine Plus reagents were
from Gibco BRL Life Technologies (Grand Island, NY).
Phosphatidylpropanol (PP) was from Avanti Polar Lipids
(Alabaster, AL). Silica LK6 Thin Layer Chromotography
(TLC) plates were from Whatman. [3H]Myristic acid and
[α-32P]dCTP were from Dupont-NEN (Boston, MA).
Molecular biology reagents (except as noted) were from
Sigma (St. Louis, MO) and phorbol 12-myristate 13-ace-
tate was from Calbiochem (La Jolla, CA). Polyclonal anti-
human PLD2- and anti-mouse PLD1 antibodies were
kindly provided by Dr. Yoshinori Nozawa (Gifu Interna-
tional Institute of Biotechnology, Japan).
Cell culture 
Mouse septal neuron x neuroblastoma hybrid SN56 cells
were maintained at 37°C in an atmosphere of 95% air, 5%
CO2 in DMEM supplemented with 10% FBS. The medi-
um was changed every 2–3 days. Cells of passage 10 to 40
were used.
Transient transfection with plasmids or antisense oligonu-
cleotides 
The pCGN expression vector containing the cDNAs of
mouse PLD2 (mPLD2) or human PLD1 (hPLD1) driven
by the CMV promoter were described previously [5,6].
An influenza-epitope (hemagglutinin-tag) is inserted in
the pCGN vector and is expressed at the N-terminus of
the PLDs. The SN56 cells were grown to about 50–70%
confluence, then transiently transfected with these
plasmids using Lipofectamine Plus reagent according to
the manufacturer's instructions. The cells were assayed
48 hours after transfection. Additional cultures were
transfected with a β-galactosidase expression plasmid
and were stained on the day of the experiment (using
staining kit from Invitrogen) to estimate transfection ef-
ficiency. The overall transfection efficiency was about
10–15%.
A mouse PLD2 antisense oligonucleotide was purchased
from Sequitur, Inc. (Natick, MA). The sequence of the
anti-mPLD2 oligonucleotide was 5'-CAUGUGCAACUG-
GCUGGAGUUCAGA-3' and corresponded to the se-
quence of mouse PLD2 cDNA (GeneBank accession
number U87557) starting at position 180. A reversed
control oligonucleotide was also used and its sequence
was 5'-AGACUUGAGGUCGGUCAACGUGUAC-3'. SN56
cells were grown to 50–60% confluence and washed
once with Opti-MEM (Gibco BRL). The oligonucleotides
were diluted in 100 µl Opti-MEM to various concentra-
tions, mixed with 100 µl of Opti-MEM containing 6 µl of
Lipofectamine and incubated at room temperature for
20 minutes. The mixture was then added to 800 µl of se-
rum-free DMEM and the cells were incubated in this me-
dium for 4 hours at 37°C and then cultured in normal
growth medium for two days before assay. A fluorescent-
dye labeled oligonucleotide was also purchased from Se-
quitur Inc. and used as a control to monitor transfection
efficiency. The transfection efficiency was about 30–
40%.
Northern blot analysis 
Northern blot analysis was carried out essentially as de-
scribed previously [25] using 20 µg of total RNA per lane
and 1% formaldehyde-agarose gel containing ethidium
bromide. The RNA was size-fractionated by electro-
phoresis and transferred to a nylon membrane (HyBond,
Amersham). The PLD probes were: PLD1 661 bp human
PLD1 cDNA fragment (GenBank accession number
U38545, pos. 951–1611) isolated from HeLa cell cDNA by
PCR, and PLD2 (GenBank accession number U87557)
excised from the pCGN-mPLD2 plasmid using endonu-
clease Xbal and Smal (3000 bp). DNA probes were la-
beled with [α-32P]dCTP with the random primer labeling
kit (Pharmacia Biotech Inc., NJ). Prehybridization and
hybridization steps were carried out at 65°C in Rapid-
Hyb solution according to manufacturer's instructions.
The blots were washed and exposed to an x-ray film (Ko-
dak BioMax MS-2 film, Sigma) with an intensifying
screen at -80°C for 4 days. Signal intensities were quan-
tified with ImageQuant software (Molecular Dynamics)
or NIH Image 1.62. Following Northern hybridization
with these probes, the blots were stripped and re-probed
with a mouse G3PDH probe for normalization purposes.
For these experiments the results are expressed as units
of band intensity normalized with G3PDH.
Western blotting of PLD isoforms 
Protein lysates from whole cells and tissues were pre-
pared with a buffer, which contained 50 mM Tris, pH 7.5,
150 mM NaCl, 1% (v/v) Nonidet P40 (NP40), 2 mM 4-(2-
BMC Neuroscience 2001, 2:16 http://www.biomedcentral.com/1471-2202/2/16aminoethyl)benzenesulphonyl fluoride, 1 µg/ml leupep-
tin, 2 µg/ml aprotinin and 2 µg/ml pepstatin. Lysates
were mixed vigorously, incubated on ice for 15 minutes
and cleared by brief centrifugation. The extracts, nor-
malized for total protein content, were separated by
SDS/PAGE and transferred to a polyvinylidene difluo-
ride membrane (Immobilon-P, Millipore Corp.). The
membrane was blocked with 5% non-fat milk in Tris-
buffered saline containing 0.15% Tween-20. The polyclo-
nal anti-human PLD2 antibody and anti-mouse PLD1
antibody were used to detect PLD2 and PLD1, respec-
tively. The membrane was then incubated with anti-rab-
bit IgG peroxidase conjugates, and proteins were
visualized using the chemiluminescence method (Lumi-
nol reagent, Santa Cruz Biotechnology) and Kodak Bi-
oMax light film (Fisher Scientific). Some blots were
stripped by incubating them at 55°C for 30 min in a solu-
tion containing Tris-HCl 62.5 mM, pH 6.7, 2% SDS and
100 mM β-mercaptoethanol, and then probed with anti-
mouse actin antibody (Sigma, St. Louis, MO) for normal-
ization purposes. Signal intensities of protein bands
were quantified with NIH Image 1.62. Approximate mo-
lecular weights were estimated using prestained stand-
ards (NEN, Boston, MA).
In vivo assay of PLD activity 
For in vivo assay, the cells were grown to subconfluence
and prelabeled with 2 µCi/ml [3H]myristic acid in
DMEM containing 10% FBS overnight. Labeled cells
were incubated in 1 ml HEPES-buffered saline solution
(HBS, composition in mM: NaCl, 145; KCl, 5; MgSO4, 1;
CaCl2, 1.8; glucose, 10; HEPES, 10; pH 7.4) at 37°C for 30
min twice to wash out the unincorporated label. The la-
beled cells were then incubated in the presence or ab-
sence of 1.5% 1-propanol with or without 100 nM PMA at
37°C for 45 min. The reaction was terminated by adding
ice-cold methanol and the lipids were extracted in a solu-
tion containing methanol/chloroform/water (1:1:1 v/v).
The lipids were dried and separated by TLC in a mobile
phase, composed of the upper phase of a mixture of ethyl
acetate/isooctane/acetic acid/water  (130:20:30:100 v/
v), and the phospholipids were visualized with l,6-diphe-
nyl-l,3,5,-hexatriene in hexane. The spots comigrating
with the appropriate phospholipid standards were
scraped off and their radioactivity was measured by liq-
uid scintillation spectrophotometry and expressed as a
percentage of the radioactivity present in the total lipids.
Acetylcholine measurements 
The cells were preincubated for 20 minutes in a choline-
free physiological salt solution (pH 7.4) consisting of 135
mM NaCl, 5 mM KCl, 1 mM CaCl2, 0.75 mM MgCl2, 10
mM glucose and 10 mM HEPES. The cells were then in-
cubated in the same buffer supplemented with 50 µM ne-
ostigmine (to inhibit acetylcholinesterase) with or
without 100 nM PMA for 45 minutes. The media were
collected for subsequent assays of ACh and choline. The
cells were scraped into 1 ml of methanol and this mixture
transferred to a tube containing 100 µl 1 M formic acid,
vortex mixed and centrifuged. The pellet was collected
for protein assay while ACh was extracted by mixing the
supernatant fluid with chloroform and water (1:2:1 v/v).
The samples were vortex mixed and centrifuged for 5
minutes at 3,000 rpm. The aqueous phase (containing
ACh) was collected and dried under a vacuum. ACh con-
tent was determined by high performance liquid chro-
matography with an enzymatic reactor containing
acetylcholinesterase and choline oxidase and an electro-
chemical detector using a commercial kit (Bioanalytical
Systems, Inc.) based on the method of Potter et al. [49]
as described previously [50]. Protein concentration was
determined by the method of Smith et al. [51].
Statistical Analysis 
Data presented in the figures were derived from 3–9 in-
dependent experiments and were analyzed using Systat
5.2.1 (SPSS Inc., Chicago, Ill) by t-test or analysis of var-
iance as appropriate. Tukey or Fisher LSD were used for
post hoc tests. Differences were considered to be signifi-
cant at p < 0.05.
Abbreviations 
1ACh, acetylcholine; ARF, ADP-ribosylation factor;
DAG, diacylglycerol; G3PDH, glyceraldehyde 3-phos-
phate dehydrogenase; MAChR, muscarinic acetylcholine
receptor; PA, phosphatidic acid; PC, phosphatidylcho-
line; PIP2, phosphatidylinositol 4, 5-bisphosphate; PKC,
protein kinase C; PLD, phospholipase D; PMA, phorbol
12-myristate 13-acetate; PP, phosphatidylpropanol;
ROS, reactive oxygen species; TLC, thin layer chroma-
tography.
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